Safety and Tolerability of Combination Therapy with Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis: A Multicenter, Retrospective, Observational Study in Japan Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020
Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Safety, Tolerability (S&T) and Pharmacokinetics (PK) of Single and Repeat Inhaled Doses of Phosphoinositide-3-Kinase Delta Inhibitor (PI3Kd) GSK2269557, Delivered via the ELLIPTATM Device to Healthy Subjects in a Phase I Trial, Including Charcoal Block. Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Late Breaking Abstract - Comparative Effectiveness of Anti-IL5/5R Versus Anti-IgE in Patients Eligible for Both (FIRE) Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
Late Breaking Abstract - TriOptimize VIII – Improvement of Lung Function with Extrafine Single Inhaler Triple Therapy – Analysis of Response Patterns by Prior Treatment from a Real-World Study. Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020
A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018
Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the Adipose Derived Stromal Cells-Stromal Vascular Fraction in Idiopathic Pulmonary Fibrosis Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018
Late Breaking Abstract - Safety and Performance of Total Lung Access to Peripheral Nodules in prospective, multi-center study Source: International Congress 2019 – Interventional pulmonology: a mixture of spices Year: 2019
Curcumin Improves Therapy of Moderate Partially Controlled Asthma: Placebo-controlled, single blind study Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021
Synergistic Drug Combination of Nintedanib and Vardenafil Inhibits Fibrosis in AKR-2B Fibroblasts Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018
A Study on Various Types of Presentations of Paediatric Tuberculosis and Response to Fixed Dose Combination (FDC). Source: Virtual Congress 2020 – The young, the old and extrapulmonary tuberculosis Year: 2020
The Effect of Lipid Profile and Obesity on the Grade of Neutropenia in Patients with Small Cell Lung Cancer Treated with Etoposide-Cisplatin as First Regimen. Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019
Monitored Anesthesia Care with Dexmedetomidine in Patients Undergoing Pleuroscopy: Effect on Oxygenation and Respiratory Function. A Prospective, Single-center Study. Source: Virtual Congress 2021 – Pleural disease and bronchoscopic lung volume reduction Year: 2021
Understanding of Pharmacokinetics and Exposure Drives use of Nintedanib as a Positive Control Reference Item in a Rat Model of Bleomycin-Induced Fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019
Late Breaking Abstract - Long-term Effect of Antithrombin or Argatroban for the Treatment of Acute Lung Injury Source: Virtual Congress 2021 – In vitro modelling of lung disease: reach out to the next dimension Year: 2021
Late Breaking Abstract - Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis (FITNESS study) Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2) Source: Virtual Congress 2020 – ALERT: Pneumothorax, cough, PAH, alveolar proteinosis Year: 2020
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Late Breaking Abstract - Bronchial Rheoplasty For Treatment of Chronic Bronchitis: 6 Month Results from a Prospective Multi-Center Study Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019